Oncopharmpod
Expanded Approvals for Durvalumab, Lu 177 vt; Portland Preview
- Author: Vários
- Narrator: Vários
- Publisher: Podcast
- Duration: 0:12:25
- More information
Informações:
Synopsis
FDA expands approvals for durvalumab (bladder cancer) and Lutetium-177 vipivotide tetraxetan (pre-taxane in metastatic prostate cancer). Portland has places.
